Join IQVIA’s esteemed panel of experts for an in-depth discussion on how AI can meet and exceed these new expectations. This webinar delves into the intersection of regulatory frameworks and technological innovation, offering insights into the future of PV and how organizations can navigate this transformative field. Key takeaways include:

What if empowering sites to successfully navigate the challenges of today’s clinical trials was the first step in supporting a patient-centric approach to research? Download your free white paper to explore practical solutions for enabling patient-centric clinical trials by using innovative solutions and technologies for the benefit of sites, sponsors and patients alike. Read now to:

January 2025 sees the implementation of the Health Technology Assessment Regulation (HTAR) developed to reduce the admin burden and equalize access of important medicines to EU patients through a collaborative framework. New concepts such as JSC and JCA act as guidance for developers but are often complex and highly competitive. Discover more about the process, including:

The role of Medical Science Liaisons (MSLs) is rapidly evolving. According to field leaders, MSLs are increasingly interacting with new kinds of external stakeholders, driving insight generation and supporting strategic company goals through internal deployment of insights. To address this, IQVIA has developed a new MSL training approach to plug the skills gap and equip MSLs for success. Explore how IQVIA:

Since the 21st Century Cures Act in 2016 and subsequent FDA guidance, regulatory frameworks have evolved to incorporate RWD and RWE - allowing a broader set of data sources, including electronic health records (EHRs), claims, and registries, to be considered for regulatory decision making. In this white paper, explore key learnings about RWD/RWE in regulatory submissions, including:

Discover how AI and automation can transform pharmacovigilance in this insightful webinar. This webinar session will explore the evolution of the ARTEMIS (Adverse Event Processing using Technology Enabled Medical and Intelligent Solution) project launched by PSPV and Sanofi Digital 6 years ago with a previous partner which was achieving significant benefits through NLP and Artificial Intelligence. Then due to unforeseen constraints Sanofi started working with IQVIA to move to a new system within 6 months and continue the journey of optimization and improvement. This partnership showcases how organizations can stay adaptable, even through shifting circumstances, to sustain momentum in digital safety innovation. Key Takeaways:

Leading experts at IQVIA Biotech explore the latest trends and provide actionable guidance for biotechs navigating the current landscape, including:

Uncover the best practice strategies for boosting hematologic oncology clinical trial success as IQVIA Biotech shares insights on:

Learn more from IQVIA Biotech experts on: